The US Food and Drug Administration (FDA) has granted accelerated approval of Voyxact (sibeprenlimab-szsi) for the reduction ...

Paris: Sanofi has announced that the European Commission has approved Dupixent (dupilumab) for the treatment of ...

Otsuka Pharmaceutical has accelerated FDA approval for Voyxact to reduce proteinuria in adults with primary IgAN at disease progression risk.

Voyxact is a treatment aimed at reducing proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). The approval was based on an interim analysis of the Phase 3 study, which showed a ...

Otsuka Holdings Co ( ($JP:4578) ) has shared an announcement. Otsuka Holdings has received accelerated FDA approval for VOYXACT, a novel treatment ...

The U.S. Food and Drug Administration has approved Otsuka's injectable drug to treat patients with a potentially ...

Regeneron Pharmaceuticals and Sanofi have won European Commission expanded approval of their blockbuster anti-inflammatory drug Dupixent for certain patients with the inflammatory skin condition ...

The European Commission has approved Sanofi and Regeneron’s Dupixent for the treatment of moderate-to-severe chronic spontaneous urticaria.

Sanofi and Regeneron’s Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...